Monte Rosa Therapeutics, Inc. Operating Lease Cost
Monte Rosa Therapeutics, Inc. (GLUE) reported Operating Lease Cost of $1.65 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. operating lease, cost for the quarter ending 2026-06-30 was $1.65M, a 1.91% increase year-over-year.
- Monte Rosa Therapeutics, Inc. operating lease, cost for the quarter ending 2026-03-31 was $1.64M, a 0.24% increase year-over-year.
- Monte Rosa Therapeutics, Inc. operating lease, cost for the quarter ending 2025-12-31 was $1.66M, a 1.34% increase year-over-year.
- Monte Rosa Therapeutics, Inc. operating lease, cost for the quarter ending 2025-09-30 was $1.65M, a 2.80% increase year-over-year.
- Monte Rosa Therapeutics, Inc. operating lease, cost for fiscal 2025 was $6.57M, a 1.12% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. operating lease, cost for fiscal 2024 was $6.50M, a 8.96% decline from fiscal 2023.
- Monte Rosa Therapeutics, Inc. operating lease, cost for fiscal 2023 was $7.14M, a 3.13% increase from fiscal 2022.
- Monte Rosa Therapeutics, Inc. operating lease, cost for fiscal 2022 was $6.92M.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 9 month as first filed | Operating Lease, Cost 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.65M 10-Q · filed 2026-08-06 | $3.29M 10-Q · filed 2026-08-06 | $4.96M derived: sum of 3 quarters · filed 2026-08-06 | $6.61M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $1.64M 10-Q · filed 2026-05-07 | $3.30M derived: sum of 2 quarters · filed 2026-05-07 | $4.96M derived: sum of 3 quarters · filed 2026-05-07 | $6.58M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $3.32M derived: sum of 2 quarters · filed 2026-03-17 | $4.94M derived: sum of 3 quarters · filed 2026-08-06 | $6.57M 10-K · filed 2026-03-17 | ||
| 2025-09-30 | $1.65M 10-Q · filed 2025-11-06 | $3.28M derived: sum of 2 quarters · filed 2026-08-06 | $4.91M 10-Q · filed 2025-11-06 | $6.55M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $1.62M 10-Q · filed 2026-08-06 | $3.26M 10-Q · filed 2026-08-06 | $4.90M derived: sum of 3 quarters · filed 2026-08-06 | $6.51M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $1.63M 10-Q · filed 2026-05-07 | $3.28M derived: sum of 2 quarters · filed 2026-05-07 | $4.88M derived: sum of 3 quarters · filed 2026-05-07 | $6.48M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $3.25M derived: sum of 2 quarters · filed 2026-03-17 | $4.85M derived: sum of 3 quarters · filed 2026-03-17 | $6.50M 10-K · filed 2026-03-17 | ||
| 2024-09-30 | $1.61M 10-Q · filed 2025-11-06 | $1.61M 10-Q · filed 2024-11-07 | $3.21M derived: sum of 2 quarters · filed 2025-11-06 | $4.86M 10-Q · filed 2025-11-06 | $4.86M 10-Q · filed 2024-11-07 | $6.45M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.60M 10-Q · filed 2025-08-07 | $3.25M 10-Q · filed 2025-08-07 | $4.84M derived: sum of 3 quarters · filed 2025-08-07 | $6.41M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $1.65M 10-Q · filed 2025-05-08 | $3.24M derived: sum of 2 quarters · filed 2025-05-08 | $4.81M derived: sum of 3 quarters · filed 2025-05-08 | $6.65M derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $3.16M derived: sum of 2 quarters · filed 2025-03-20 | $5.00M derived: sum of 3 quarters · filed 2025-03-20 | $7.14M 10-K · filed 2025-03-20 | ||
| 2023-09-30 | $1.57M 10-Q · filed 2024-11-07 | $3.41M derived: sum of 2 quarters · filed 2024-11-07 | $5.55M 10-Q · filed 2024-11-07 | $7.62M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.98M 10-Q · filed 2024-08-08 | $6.05M derived: sum of 3 quarters · filed 2024-08-08 | $8.20M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $2.14M 10-Q · filed 2024-05-09 | $4.21M derived: sum of 2 quarters · filed 2024-05-09 | $6.36M derived: sum of 3 quarters · filed 2024-05-09 | $8.56M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $4.22M derived: sum of 2 quarters · filed 2024-03-14 | $6.42M derived: sum of 3 quarters · filed 2024-03-14 | $6.92M 10-K · filed 2024-03-14 | ||
| 2022-09-30 | $2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.36M derived: sum of 2 quarters · filed 2023-11-09 | $4.86M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $2.70M 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | $502.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |